Subscribe to our Newsletters !!
Using antibodies in different laboratory settings,
There are a few things to avoid while utilizing an
Sepsis is an overly amplified response of the body
TM Media is pleased to add the prestigious Elets 6
Alembic Pharmaceuticals Limited (Alembic) today an
It is important to understand that natural remedie
Dear Readers,Welcome to the latest issue of Microb
Mumbai, India/ New Jersey, United States, September 7, 2022: Cipla Limited (BSE: 500087; NSE: CIPLA EQ) (“Cipla”) announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Lenalidomide Capsule 5 mg, 10 mg, 15 mg and 25 mg from the United States Food and Drug Administration (US FDA).
Cipla’s Lenalidomide Capsules are the AB-rated therapeutic equivalent generic version of Bristol Myers Squibb’s (Celgene) Revlimid® (Lenalidomide) Capsules.
Lenalidomide is an immunomodulatory prescription drug which is indicated for several hematological malignancies in adults such as Multiple Myeloma, Myelodysplastic syndromes, Mantle cell lymphoma, Follicular lymphoma, and Marginal Zone lymphoma. Depending on the type of cancer, it can be used as monotherapy or combination as a part of first line regimen, maintenance regimen or relapsed settings.
Lenalidomide capsules are not to be used by pregnant women. It is not known if lenalidomide is safe and effective for children. Lenalidomide Capsules should not be used to treat people with chronic lymphocytic leukemia (CLL) outside of a controlled clinical trial.
According to IQVIA (IMS Health), Revlimid® (Lenalidomide) Capsules had US sales of approximately $ 2.58 billion for the 12-month period ending June 2022.
The product will be available for shipping soon.
